



BACKGROUND

- Between 2020-21, alcohol use disorder (AUD) claimed the lives of almost 200,000 Americans (Centers for Disease Control and Prevention, 2024).
- Evidence-based treatments exist but are not effective for many, with heterogeneity of AUD likely a key contributor (Litten et al., 2016).
- Identifying individual predictors of potential treatment response could be one key to improving outcomes. One promising candidate predictor could be *incentive* salience attribution (ISA):

In cued reinforcement paradigms, the degree to which value (i.e., incentive salience) is associated with the cue that predicts the desired outcome (the *sign*) and/ or with the outcome itself (the goal).

Work with non-AUD samples finds reliable individual ISA differences (whether individuals respond to signs as salient stimuli or not; Versace et al., 2019) As a first step to study ISA as a candidate treatment predictor in AUD, this study tested if ISA differences are also measurable in individuals with AUD.


METHODS

- 24 participants with AUD have completed this ongoing observational study.
- **ISA task**: Participants see images varying in inherent hedonic content (pleasant, unpleasant, or neutral) and intensity. One low-intensity image type is consistently followed by a food reward (M&M candy) 2s after pic onset

M&M

CAPTURING ISA DIFFERENCES

- **Measurement Modality:** 32-channel brain electroencephalography (BrainVision active EEG system)
- Salience Index: An event-related brain response to pictures whose amplitude scales with image salience – the late positive potential (LPP).





CLASSIFYING ISA DIFFERENCES


- \circ <u>Sign Trackers</u>: individuals with >3µV larger LPP for pleasant and food-predicting images vs. neutral
- \circ <u>Goal Trackers</u>: Individuals with >3µV larger LPP for pleasant than food and $<3\mu$ V food vs. neutral diff.

Sign vs. Goal Tracking in Alcohol Use Disorder: Predicting Problem Alcohol Use Using A Neurophysiological **Endophenotype of Reward-Based Incentive Salience Attribution** Sophia Taber, Samantha LaPorta, B.A., Rhia Walton, M.A., Lisa M. McTeague, PhD, & Christopher T. Sege, PhD Medical University of South Carolina

RESULTS

Paired t-test results convey that all participants showed consistent LPP amplitude enhancement for highly unpleasant, t(23)=9.4, p<.001, and highly pleasant, t(23)=8.6, p<.001, pictures compared to neutral pictures, shown in **Figure 1**. Applying our classification scheme revealed half (n=12) of participants who also showed LPP enhancement for lowintensity food-predicting pictures (i.e., signs) compared to neutral images, t(11)=7.6, p<.001, and another half who showed no difference between food-predicting and neutral pictures, t(11)=-0.3, p=.744 (Figures 2 and 3). On average, sign trackers consumed less M&Ms than goal trackers (Figure 4), but there were no statistical differences comparing their AUD symptoms (Figure 5) or past-month alcohol consumption (Figure 6). LATE POSITIVE POTENTIAL RESPONSE IN TASK Figure 1: LPP Response All Participants Man Martin Martin Martin (h/) 2 1 Time (s) —Food LPP —Pleasant - High LPP —Alcohol LPP -Neutral Objects LPP -Unpleasant - High LPP

INCENTIVE SALIENCE ATTRIBUTION DIFFERENCES IN RESPONSE TO TASK







Figure 2: LPP Response for Goal vs. Sign Trackers Figure 3: LPP Response Differences for Goal vs. Sign Trackers



| • | Cen https deat |
|---|------------------------|
| • | Litte alco doi:1 |
| • | Vers porn eatir |
| • | Vers e-ciç |





CONCLUSIONS

Key Finding: ISA Differences were readily detectable in individuals with AUD:

- Sign trackers showed robust LPP enhancement for images that were not inherently salient but did predict a general reward (candy)
- Goal trackers showed minimal LPP for rewardpredicting low-intensity images
- All participants showed LPP enhancement to inherently emotional images (goals)

Of note: ISA differences were apparent in a task using general rewards, rather than disorder-specific reward (i.e., alcohol).

• In this study, ISA distinctions also predicted task behavior such that M&M consumption was greater for goal trackers than sign trackers - opposite to prior findings (Versace et al., 2019).

• More work is needed to determine if different patterns arise with alcohol-related rewards

ISA also did not predict alcohol use severity but this is consistent with findings from other samples (e.g., cigarette smokers; Versace et al., 2023). At the same time, ISA differences might still predict *treatment outcome* variables (response to treatment, relapse risk) like in that

Findings support a biological index of ISA (LPP response to reward-predicting images) for further study as a treatment predictor candidate in AUD.

FUTURE DIRECTIONS

Future studies should compare results from an alcoholnon-specific task with results from a version that uses alcohol rewards - to determine if similar or different patterns arise with different rewards

Also, future investigations should determine if classifying individuals with AUD based on ISA accurately predicts standardized AUD treatment outcomes – including treatment response and treatment response durability

REFERENCES

nters for Disease Control and Prevention. (2024, July 3). Facts about U.S. deaths from excessive alcohol abuse. s://www.cdc.gov/alcohol/facts-stats/?CDC AAref Val=https://www.cdc.gov/alcohol/features/excessive-alcohol ths html

en R.Z., Wilford B.B., Falk D.E., Ryan M.L., & Fertig J.B. (2016). Potential medications for the treatment of phol use disorder: An evaluation of clinical efficacy and safety. Substance Abuse, 37(2), 286-298. 10.1080/08897077.2015.1133472

sace, F., Frank, D.W., Stevens, E M., Deweese, M.M., Guindani, M., & Schembre, S.M. (2019). The reality of "food n": Larger brain responses to food-related cues than to erotic images predict cue-induced ing. Psychophysiology, 56(4), e13309. https://doi.org/10.1111/psyp.13309

sace, F., Kypriotakis, G., & Pluta, D. (2023). Neuroaffective reactivity profiles are associated with vulnerability to igarette use. Drug and alcohol dependence, 247, 109871. https://doi.org/10.1016/j.drugalcdep.2023.109871

ACKNOWLEDGEMENTS

This work was supported in part by NIH grant R25 DA020537